Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Ray McDermott et al.|Journal of Clinical Oncology|2018Cited by 2.1k
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142Thierry André, Michael J. Overman, Sara Lonardi et al.|Annals of Oncology|2022Cited by 253
mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with EverolimusFabio Gelsomino, Gabriele Luppi|Cancers|2020Cited by 11
New Frontiers of Biomarkers in Metastatic Colorectal Cancer: Potential and Critical IssuesBianca Medici, Fabio Gelsomino|International Journal of Molecular Sciences|2025Cited by 6